Table 2.
Physician-reported patient comorbidities and current therapies by NYHA class.
| All patients N = 208 | Patients who were NYHA class I/II n = 156 | Patients who were NYHA class III n = 43 | |
|---|---|---|---|
| Comorbidities, n (%)* | |||
| Heart failure | 115 (55.3) | 86 (55.1) | 29 (67.4) |
| Hypertension | 115 (55.3) | 80 (51.3) | 29 (67.4) |
| Heart failure with preserved ejection fraction | 100 (48.1) | 78 (50.0) | 20 (46.5) |
| Carpel tunnel syndrome | 100 (48.1) | 78 (50.0) | 20 (46.5) |
| Hyperlipidemia | 84 (40.4) | 53 (34.0) | 23 (53.5) |
| Diabetes mellitus | 39 (18.8) | 28 (17.9) | 9 (20.9) |
| Kidney disease | 36 (17.3) | 20 (12.8) | 12 (27.9) |
| Cancer (other than skin) | 32 (15.4) | 19 (12.2) | 11 (25.6) |
| Neuropathy | 24 (11.5) | 14 (9.0) | 10 (23.3) |
| Depression | 22 (10.6) | 16 (10.3) | 5 (11.6) |
| Obesity | 21 (10.1) | 13 (8.3) | 6 (14.0) |
| Anxiety | 17 (8.2) | 12 (7.7) | 4 (9.3) |
| Liver disease | 5 (2.4) | 4 (2.6) | 1 (2.3) |
| Autonomic nervous system disease | 4 (1.9) | 2 (1.3) | 2 (4.7) |
| Other† | 109 (52.4) | 78 (50.0) | 24 (55.8) |
| Current symptomatic therapies, n (%)* | |||
| Anti-hypertensives | 174 (83.7) | 126 (80.8) | 39 (90.7) |
| Diuretics | 145 (69.7) | 105 (67.3) | 36 (83.7) |
| Anticoagulants | 132 (63.5) | 100 (64.1) | 23 (53.5) |
| Antiarrhythmic therapy including implanted cardioverter-defibrillators | 65 (31.3) | 58 (37.2) | 6 (14.0) |
| Antidepressants | 24 (11.5) | 17 (10.9) | 7 (16.3) |
| Steroids | 17 (8.2) | 15 (9.6) | 1 (2.3) |
| Drugs for neuropathy | 14 (6.7) | 10 (6.4) | 4 (9.3) |
NYHA, New York Heart Association.
*
More than one can apply.
†
“Other” was a pre-specified category selected by the investigator. The nature of the comorbidity was not indicated.